First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors.
Emiliano Calvo
No relevant relationships to disclose
Karim Adnane Benhadji
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Analia Azaro
No relevant relationships to disclose
Ignacio Duran
No relevant relationships to disclose
Guillem Argiles
No relevant relationships to disclose
Valentina Boni
No relevant relationships to disclose
Ute Ohnmacht
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Johan Wallin
Employment or Leadership Position - Lilly
William Mark Bumgardner
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Jordi Rodon Ahnert
Consultant or Advisory Role - Lilly